Oxford COVID-19 vaccine efficacy would look higher if trial tested for severe virus

Speaking in a briefing, Andrew Pollard, director of the Oxford Vaccine Group, said it is hard to explain the different efficacy rates between the AstraZeneca/Oxford shot and the other vaccines developed by Pfizer and BioNTech and one by Moderna.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news